Monitor for subsequent clinical readouts for LB2102 (dose escalation, expansion) and any regulatory updates for CARVYKTI label expansion; early data support pipeline value but not near-term revenue.
Price Chart
Executive Summary
Legend Biotech presented early clinical data for LB2102 (DLL3 CAR-T) in SCLC/LCNEC at ASCO, showing manageable safety and encouraging efficacy (28.6% ORR at higher doses), alongside updated CARVYKTI data reinforcing its durable efficacy in multiple myeloma. The data support pipeline progress but remain early-stage; no financial impact is reported.
Key Facts
- LB2102 Phase 1 data: ORR 20% overall, 28.6% at higher dose levels, DCR 78.6% at higher doses, median duration of response 6.5 months.
- CARVYKTI data from CARTITUDE-4 show 30-month OS >85% in high-risk and standard-risk subgroups; no new safety signals.
- LB2102 licensed to Novartis globally; Legend retains Phase 1 in US.
- CARVYKTI approved in 18 countries, >10,000 patients treated.
- No financial or guidance figures provided in the press release.
Financial Impact
No financial figures disclosed; stock impact likely from clinical sentiment rather than revenue.
Risk Factors
- LB2102 is in early Phase 1; efficacy and safety remain unproven in larger trials.
- Competition from other DLL3-targeted therapies (e.g., bispecifics, ADCs).
- CARVYKTI faces potential competition from other BCMA CAR-T and bispecifics.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304508 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 6-K | $19.80 | awaiting T+20 | — | $21.56 (+8.89%) |
Oct 13, 2026 14d ago | 6-K | $17.88 | awaiting T+20 | — | $21.56 (+20.58%) |
Sep 29, 2026 28d ago | 144 | $18.82 $21.16 | ▲ +12.41% | ▲ +11.75% | $21.56 (+14.56%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $21.56 (+12.82%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $21.56 (+12.82%) |
Sep 15, 2026 6w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $21.56 (+22.01%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $21.56 (+16.35%) |
Aug 11, 2026 11w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $21.56 (−1.24%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $21.56 (−11.88%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $21.56 (+11.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers